Advertisement

Exkurs: Wirkverlust und „Therapieresistenz“

  • W. Poewe

Zusammenfassung

In der Mehrzahl der Fälle gelingt es, mit einer der verschiedenen möglichen Strategien der Ersteinstellung eines Patienten mit idiopathischem Parkinson-Syndrom zu einem befriedigenden Therapieresultat zu gelangen. Bei L-Dopa-Monotherapie wird in Abhängigkeit von der gewählten Dosis innerhalb des ersten Behandlungsjahres bei bis zu 90% der Patienten ein ausreichender Effekt erzielt (Shaw et al. 1980, Poewe et al. 1986a, s. auch Tabelle 8.2). Ähnlich ist die Situation bei Kombinationsbehandlung von L-Dopa mit einem Dopamin- (DA)-Agonisten (Rinne 1989), während nur knapp 60% auf Monotherapie mit einem DA-Agonisten im ersten Jahr hinlänglich gut ansprechen (Lees und Stern 1983, Rascol et al. 1984).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Agid Y, Ruberg M, Dubois B, Javoy-Agid F (1983) Biochemical substrates of mental disturbances in Parkinson’s disease. Adv Neurol 40: 211–218Google Scholar
  2. Barbeau A (1976) Six years of high-level levodopa therapy in severely akinetic parkinsonian patients. Arch Neurol 33: 333–338PubMedCrossRefGoogle Scholar
  3. Barbeau A, Roy M (1976) Six-year results of treatment with levodopa plus benserazide in Parkinson’s disease. Neurology 26: 399–404PubMedCrossRefGoogle Scholar
  4. Battistin, L, Meneghetti G, Rigotti S, Saia A (1978) A long-term treatment of Parkinson’s disease with L-Dopa and doipa-decarboxylase inhibitor: therapeutic results and side-effects. Acta Neurol Scand 57: 186–192PubMedCrossRefGoogle Scholar
  5. Birkmayer W, Riederer P, Ambrozi L, Youdim MBH (1977) Implications of combined treatment with “Madopar” and 1-deprenyl in Parkinson’s disease: a long-term study. Lancet i: 343–349Google Scholar
  6. Butzer JF, Silver DE, Sahs AL (1975) Amantadine in Parkinson’s disease. Neurology 25: 603–606PubMedCrossRefGoogle Scholar
  7. Carter JH, Nutt JG, Woodward WR, Hatcher L, Trotman L (1989) Amount and distribution of dietary protein affectsthe clinicalresponse to levodopa. Neurology 39: 552–556PubMedCrossRefGoogle Scholar
  8. Cedarbaum JM (1989) The promise and limitations of controlled-release oral levodopa administration. Clin Neuropharmacol 12: 147–166PubMedCrossRefGoogle Scholar
  9. Duvoisin RC (1967) Cholinergic-anticholinergic antagonism in parkinsonism. Arch Neurol 17: 124–136PubMedCrossRefGoogle Scholar
  10. Erni W, Held K (1987) The hydrodynamically balanced system: a novel principle of controlled drug release. Eur Neurol 27 [Suppl 1]: 21–27PubMedCrossRefGoogle Scholar
  11. Evans MA, Broe GA, Triggs EJ, Cheung M, Creasy H, Paull PD (1981) Gastric emptying rate and the systemic availability of levodopa in the elderly parkinsonian patient. Neurology 31: 1288–1294PubMedCrossRefGoogle Scholar
  12. Fischer PA, Schneider E, Jacobi P (1984) Ergebnisse der medikamentösen Parkinson-Therapie. Modifizierende und limitierende Faktoren. In: Fischer PA (Hrsg) Parkinson plus. Springer, Berlin Heidelberg New York, S 4–7CrossRefGoogle Scholar
  13. Frankel JP, Kempster PA, Bovingdon M, Webster R, Lees AJ, Stern GM (1989) The effects of oral protein on the absorption of intraduodenal levodopa and motor performance. J Neurol Neurosurg Psychiatry 52: 1063–1067PubMedCrossRefGoogle Scholar
  14. Frankel JP, Lees AJ, Kempster PA, Stern GM (1990) Subcutaneous apomorphine in the treatment of Parkinson’s disease. J Neurol Neurosurg Psychiatry 53: 96–101PubMedCrossRefGoogle Scholar
  15. Friedman JH, Lannon MC (1990) Clozapine-responsive tremor in Parkinson’s disease. Mov Disord 5: 225–229PubMedCrossRefGoogle Scholar
  16. Gancher ST, Nutt JG, Woodward W (1988) Response to brief levodopa infusions in Parkinsonian patients with and without motor fluctuations. Neurology 38: 712–716PubMedCrossRefGoogle Scholar
  17. Gibb WRG, Lees AJ (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 51: 745–752PubMedCrossRefGoogle Scholar
  18. Golbe LI (1988) Deprenyl as symptomatic therapy in Parkinson’s disease. Clin Neuropharmacol 11: 387–400PubMedCrossRefGoogle Scholar
  19. Hughes AJ, Lees AJ, Stern GM (1990) Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes. Lancet 336: 32–34PubMedCrossRefGoogle Scholar
  20. Kempster PA, Gibb WRG, Stern GM, Lees AJ (1989a) Asymmetry of substantia nigra neuronal loss in Parkinson’s disease and its relevance to the mechanism of levodopa related motor fluctuations. J Neurol Neurosurg Psychiatry 52: 72–76PubMedCrossRefGoogle Scholar
  21. Kempster PA, Frankel JP, Bovingdon M, Webster R, Lees AJ, Stern GM (1989b) Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson’s disease. J Neurol Neurosurg Psychiatry 52: 718–723PubMedCrossRefGoogle Scholar
  22. Kurlan R, Rubin AJ, Miller C et al. (1986) Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations. Ann Neurol 20: 262–265PubMedCrossRefGoogle Scholar
  23. Lang AE (1984) Treatment of Parkinson’s disease with agents other than levodopa and dopamine agonists: controversies and new approaches. Can J Neurol Sci 2: 210–220Google Scholar
  24. Lee JE, Sweet RD, Mcdowell FH (1971) Treatment of parkinsonism with levodopa: follow-up after 2 years of treatment. Ann Intern Med 75: 703–708PubMedCrossRefGoogle Scholar
  25. Leenders KL, Poewe WH, Palmer AJ, Brenton D, Frackowiack RSJ (1986a) Inhibition of L-18(F)fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography. Ann Neurol 20: 258–261PubMedCrossRefGoogle Scholar
  26. Leenders KL, Palmer AJ, Quinn NP et al. (1986b) Brain dopamine metabolism in patients with Parkinson’s disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry 49: 853–860PubMedCrossRefGoogle Scholar
  27. Lees AJ, Stern GM (1983) Sustained bromocriptine therapy in 50 previously untreated patients with Parkinson’s disease. Adv Neurol 37: 17–21PubMedGoogle Scholar
  28. Liebermann AN, Goldstein M, Leibowitz M, Gopinathan G, Neophytides A, Hiesiger E, Nelson J, Walker R (1984) Long-term treatment with pergolide: decreased efficacy with time. Neurology 34: 223–226CrossRefGoogle Scholar
  29. Markham CH, Treciokas LJ, Diamond SG (1974) Parkinson’s disease and levodopa: a five year follow up and review. West J Med 121: 188–206PubMedGoogle Scholar
  30. Marsden CD, Parkes JD (1977) Success and problems of long-term levodopa therapy in Parkinson’s disease. Lancet i: 345–349CrossRefGoogle Scholar
  31. Mcdowell FH, Sweet R (1979) Ten-year follow-up study of levodopa-treated patients with Parkinson’s disease. Adv Neurol 24: 475–480Google Scholar
  32. Mena I, Cotzias GC (1978) Protein intake and treatment of Parkinson’s disease with levodopa. N Engl J Med 292: 131–184Google Scholar
  33. Mouradian MM, Chase TN (1988) Central mechanisms and levodopa response fluctuations in Parkinson’s disease. Clin Neuropharmacol 11: 378–385PubMedCrossRefGoogle Scholar
  34. Mouradian MM, Juncos JL, Fabbrini G, Schlegel J, Bartko JJ, Chase TN (1988) Motor fluctuations in Parkinson’s disease: central pathophysiological mechanisms, part 2. Ann Neurol 24: 372–378PubMedCrossRefGoogle Scholar
  35. Nutt JG, Fellman JH (1984) Pharmacokinetics of levodopa. Clin Neuropharmol 7: 35–49CrossRefGoogle Scholar
  36. Nutt JG, Woodward WA, Hammerstad JP, Carter JH, Anderson JL (1984) The ‘on-off’ phenomenon in Parkinson’s disease: relation to levodopa absorption and transport. N Engl J Med 310: 483–488PubMedCrossRefGoogle Scholar
  37. Obeso J, Luquin MR, Martinez-Lage JM (1986) Intravenous lisuride corrects oscillations in motor performance in Parkinson’s disease. Ann Neurol 19: 31–35PubMedCrossRefGoogle Scholar
  38. Obeso JA, Luquin MR, Martinez-Lage JM (1988) Subcutaneous administration of lisuride in the treatment of complex motor fluctuations in Parkinson’s disease. J Neural Transm [Suppl] 27: 17–25Google Scholar
  39. Oertel WH, Gasser T, Ippisch R, Trenkwalder C, Poewe WH (1989) Apomorphine test for dopaminergic responsiveness. Lancet i: 1263Google Scholar
  40. Ordenstein L (1967) Sur la Daralvsie aaitante e la sclérose en Dlaque généralisé. Martinet, ParisGoogle Scholar
  41. Pakkenberg H, Pakkenberg B (1986) Clozapine in the treatment of tremor. Acta Neurol Scand 73: 295–297PubMedCrossRefGoogle Scholar
  42. Parkes JD, Zilkha KJ, Calver DM, Knill-Jones RP (1970) Controlled trial of amantadine hydrochloride in Parkinson’s disease. Lancet i: 259–262CrossRefGoogle Scholar
  43. Parkes JD, Baxter RCH, Curzor G, Knill-Jones RP, Knott PJ, Marsden CD, Tattersall R, Vollum B (1971) Treatment of Parkinson’s disease with amantadine and levodopa. Lancet i: 1083–1085CrossRefGoogle Scholar
  44. Pincus JH, Barry K (1987) Influence of dietary protein on motor fluctuations in Parkinson’s disease. Arch Neurol 44: 270–272PubMedCrossRefGoogle Scholar
  45. Pincus JH, Barry K (1988) Protein redistribution diet restores motor function in patients with dopa-resistant “off” periods. Neurology 38: 481–483PubMedCrossRefGoogle Scholar
  46. Poewe W, Kleedorfer B, Wagner M, Benke T, Gasser T, Oertel W (1989a) Side-effects of subcutaneous apomorphine in Parkinson’s disease. Lancet i: 1084–1085CrossRefGoogle Scholar
  47. Poewe WH, Lees AJ, Stern GM (1986a) Low-dose L-Dopa therapy in Parkinson’s disease: a 6 year follow up study. Neurology 36: 1528–1530PubMedCrossRefGoogle Scholar
  48. Poewe WH, Lees AJ, Stern GM (1986b) Treatment of motor fluctuations in sustained release preparation of L-dopa: clinical and pharmacokinetic observations. Clin Neuropharmacol 9: 430–439PubMedCrossRefGoogle Scholar
  49. Poewe WH, Kleedorfer B, Gerstenbrand F (1989a) Therapeutische Erfahrungen mit einem slowrelease-Präparat von L-Dopa (Madopar HBS) bei Patienten mit fortgeschrittener ParkinsonKrankheit. Nervenarzt 60: 294–298PubMedGoogle Scholar
  50. Poewe WH, Kleedorfer B, Gerstenbrand F, Oertel WH (1989b) Die Behandlung von ParkinsonPatienten mit L-Dopa- Wirkungsfluktuation mittels subkutanen Apomorphingaben. Akt Neurol 16: 73–77CrossRefGoogle Scholar
  51. Quinn N (1989) Multiple system atrophy — the nature of the beast. J Neurol Neurosurg Psychiatry [Suppl]: 78–89Google Scholar
  52. Quinn N, Parkes JD, Marsden CD (1984) Control of on-off phenomena by continuous intravenous infusion of levodopa. Neurology 34: 1131–1136PubMedCrossRefGoogle Scholar
  53. Rajput AH, Stern W, Laverty WH (1984) Chronic low-dose levodopa therapy in Parkinson’s disease: an argument for delaying levodopa therapy. Neurology 34: 991–996PubMedCrossRefGoogle Scholar
  54. Rascol A, Montrastuc JL, Rascol O (1984) Should dopamine agonists be given early or late in the treatment of Parkinson’s disease? Can J Neurol Sci 11: 229–232PubMedGoogle Scholar
  55. Riley D, Lang AE (1988) Practical application of a low protein diet for Parkinson’s disease. Neurology 38: 1026–1031PubMedCrossRefGoogle Scholar
  56. Rinne UK (1987) Dopamine agonists as primary treatment in Parkinson’s disease. Adv Neurol 45: 519–524PubMedGoogle Scholar
  57. Rinne UR (1989) Lisuride, a dopamine agonist in the treatment of early Parkinson’s disease. Neurology 39: 336–339PubMedCrossRefGoogle Scholar
  58. Sage JL, Trookin S, Sonsalla PK, Heikkila R, Duvoisin RC (1988) Long-term duodenal infusion of levodopa for motor fluctuations in Parkinsonism. Ann Neurol 24: 87–89PubMedCrossRefGoogle Scholar
  59. Schwab RS, England AC, Poskanzer DL, Young RR (1969) Amantadine in the treatment of Parkinson’s disease. J Am Med Assoc 208: 1168CrossRefGoogle Scholar
  60. Shaw KM, Lees AJ, Stern GM (1980) The impact of treatment with Levodopa on Parkinson’s disease. QJ Med 49: 283–293Google Scholar
  61. Shoulson I, Glaubiger, GA, Chase TN (1975) ‘Onoff’ response. Clinical and biochemical correlations during oral and intravenous levodopa adminstration in parkinsonian patients. Neurology 25: 1144–1148PubMedCrossRefGoogle Scholar
  62. Stibe CMH, Lees AJ, Kempster PA, Stern GM (1988) Subcutaneous apomorphine in parkinsonian on-off-oscillations. Lancet i: 403–06CrossRefGoogle Scholar
  63. Stocchi F, Ruggieri S, Antonini A et al. (1988) Subuctaneous lisuride infusion in Parkinson’s disease: clinical results using different modes of administration. J Neural Transm 27: 27–33Google Scholar
  64. Stocchi F, Ruggieri S, Braurante L, De Pandis F, Agnoli A (1992) Intrajejunal infusion of L-Dopa methylester. Proceedings of the European Conference on Parkinson’s disease and Extrapyramidal Disorders, Rome, July 10–14, 1990. J Libbey (in Druck)Google Scholar
  65. Sweet RD, Mcdowell FH (1975) Five years treatment of Parkinson’s disease with levodopa: therapeutic results and survival of 100 patients. Ann Intern Med 83: 456–463PubMedCrossRefGoogle Scholar
  66. The Parkinson Study Group (1989) Effect of deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 321: 1364— 1371CrossRefGoogle Scholar
  67. Timberlake WH, Vance MA (1978) Four-year treatment of patients with parkinsonism using amantadine alone or with levodopa. Ann Neurol 3: 119–128PubMedCrossRefGoogle Scholar
  68. Vaamonde J, Luquin MR, Obeso JA (1992) Subcutaneous lisuride infusion in Parkinson’s disease: response to chronic ad ministration in 34 patients. Proceedings of the European Conference on Parkinson’s disease and Extrapyramidal Disorders, Rome, July 10–14, 1990. J Libbey (in Druck)Google Scholar
  69. Wade LA, Katzman A (1975) Synthetic amino acids and the nature of levodopa transport at the blood-brain barrier. J Neurochem 25: 837–842PubMedCrossRefGoogle Scholar
  70. Wade DN, Mearrick PT, Morris JL (1973) Active transport of L-Dopa in the intestine. Nature 242: 463–465PubMedCrossRefGoogle Scholar
  71. Wade DN, Mearrick PT, Burkett et al. (1974) Variability of levodopa absorption in man. Aust NZ J Med 4: 138–143CrossRefGoogle Scholar
  72. Yahr MD (1976) Evaluation of long-term therapy in Parkinson’s disease: mortality and therapeutic efficacy. In: Birkmayer W, Hornykiewicz O (eds) Advances in parkinsonism. Editiones Roche, Basel, pp 435–443Google Scholar
  73. Yeh KC, August TT, Bush DF et al. (1989) Pharmacokinetics and bioavailability of Sinement CR: a summary of human studies. Neurology 39: 25–38PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 1992

Authors and Affiliations

  • W. Poewe

There are no affiliations available

Personalised recommendations